GILD vs LGND: fair value comparison
Gilead Sciences, Inc. and Ligand Pharmaceuticals Incorporated · Updated 2026-09-06
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, GILD currently sits closer to the top of our discount ranking. LGND carries the stronger quality grade.
| GILD | LGND | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $151.00 | $292.04 |
| 12-month range | $119.79–$150.03 | $179.07–$312.01 |
| Sector rank | #104 of 113 Healthcare | #108 of 113 Healthcare |
| Quality grade | D | B |
| Leverage | Moderate | Moderate |
| Margin trend | Expanding | — |
| Revenue growth | Modest | — |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | Uptrend | Uptrend |
| DCF cross-check | Undervalued | — |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: GILD fair value analysis · LGND fair value analysis